| Haley C Zigray, MD | |
|
1221 Whipple St, Eau Claire, WI 54703-5200 | |
| (715) 838-5222 | |
| Not Available |
| Full Name | Haley C Zigray |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 1221 Whipple St, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952939100 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 69698 (Minnesota) | Secondary |
| 207P00000X | Emergency Medicine | 30864 (Minnesota) | Secondary |
| 207P00000X | Emergency Medicine | 81364 (Wisconsin) | Primary |
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
Calcium deposits in coronary arteries provide a strong predictor for possible future heart attacks and cardiac diseases, and detecting such deposits can be valuable for promoting overall cardiac health, according to a study led by the University of California, Irvine and appearing in the March 28 issue of the New England Journal of Medicine.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
The human intestine may provide up to 10 percent of blood cells in circulation from its own reservoir of blood-forming stem cells, a surprising new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.
An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.
BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).
› Verified 8 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1154372944 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000001 |
News Archive
Calcium deposits in coronary arteries provide a strong predictor for possible future heart attacks and cardiac diseases, and detecting such deposits can be valuable for promoting overall cardiac health, according to a study led by the University of California, Irvine and appearing in the March 28 issue of the New England Journal of Medicine.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
The human intestine may provide up to 10 percent of blood cells in circulation from its own reservoir of blood-forming stem cells, a surprising new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.
An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.
BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).
› Verified 8 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740239557 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000112 |
News Archive
Calcium deposits in coronary arteries provide a strong predictor for possible future heart attacks and cardiac diseases, and detecting such deposits can be valuable for promoting overall cardiac health, according to a study led by the University of California, Irvine and appearing in the March 28 issue of the New England Journal of Medicine.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
The human intestine may provide up to 10 percent of blood cells in circulation from its own reservoir of blood-forming stem cells, a surprising new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.
An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.
BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).
› Verified 8 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1912958026 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000215 |
News Archive
Calcium deposits in coronary arteries provide a strong predictor for possible future heart attacks and cardiac diseases, and detecting such deposits can be valuable for promoting overall cardiac health, according to a study led by the University of California, Irvine and appearing in the March 28 issue of the New England Journal of Medicine.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
The human intestine may provide up to 10 percent of blood cells in circulation from its own reservoir of blood-forming stem cells, a surprising new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.
An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.
BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).
› Verified 8 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700837812 PECOS PAC ID: 4385553627 Enrollment ID: O20171012001230 |
News Archive
Calcium deposits in coronary arteries provide a strong predictor for possible future heart attacks and cardiac diseases, and detecting such deposits can be valuable for promoting overall cardiac health, according to a study led by the University of California, Irvine and appearing in the March 28 issue of the New England Journal of Medicine.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
The human intestine may provide up to 10 percent of blood cells in circulation from its own reservoir of blood-forming stem cells, a surprising new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.
An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.
BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Haley C Zigray, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Haley C Zigray, MD 1221 Whipple St, Eau Claire, WI 54703-5200 Ph: (715) 838-5222 |
News Archive
Calcium deposits in coronary arteries provide a strong predictor for possible future heart attacks and cardiac diseases, and detecting such deposits can be valuable for promoting overall cardiac health, according to a study led by the University of California, Irvine and appearing in the March 28 issue of the New England Journal of Medicine.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
The human intestine may provide up to 10 percent of blood cells in circulation from its own reservoir of blood-forming stem cells, a surprising new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.
An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.
BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).
› Verified 8 days ago
Ashley Ann Jacobson, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Jeffrey J Groshens, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 733 W Clairemont Ave, Eau Claire, WI 54701 Phone: 715-838-5222 | |
Mr. Daniel David Kaisler, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-3311 | |
Matthew Olmstead, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-3635 | |
Tracy Marko, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Cheryl M Colbenson, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 900 W Clairemont Ave, Eau Claire, WI 54701 Phone: 715-717-4121 | |
John Patrick Frawley, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-5222 |